Trial Summary
What is the purpose of this trial?This trial tests a custom-made vaccine for ovarian cancer, used with Nivolumab. It targets ovarian cancer patients who need new treatment options. The vaccine boosts the immune response using the patient's own cancer proteins, while Nivolumab keeps the immune system active.
Eligibility Criteria
This trial is for women over 18 with certain types of ovarian cancer who are in good health and not pregnant. They must have a performance status indicating they can care for themselves, agree to use contraception, and be willing to follow the study's procedures. Those with non-epithelial tumors, serious illnesses besides cancer, or recent major surgery cannot join.Inclusion Criteria
I can take care of myself but might not be able to do heavy physical work.
I am 18 years old or older.
I have been diagnosed with a specific type of ovarian, peritoneal, or fallopian tube cancer.
+7 more
Exclusion Criteria
Pregnant or nursing women
I have or had an autoimmune disease, with some exceptions.
Underlying medical condition, psychiatric condition, or social situation that would compromise study administration as per protocol or compromise the assessment of AEs
+12 more
Participant Groups
The study tests a new vaccine called NeoVax alongside Nivolumab (Opdivo®) in patients with ovarian cancer. Participants will receive both treatments and be monitored to see how well they work together against their cancer.
2Treatment groups
Experimental Treatment
Group I: Stanfard Platinum with Surgical or Core Needle BiopsyExperimental Treatment3 Interventions
* A total of 5 NeoVax immunizations will be administered over a 3-week period
* Two booster vaccinations will be given at Week 12
* Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks.
* Will undergo required surgical or core needle biopsy at first recurrence with progression free interval
Group II: Stanfard PlatinumExperimental Treatment2 Interventions
* A total of 5 NeoVax immunizations will be administered over a 3-week period
* Two booster vaccinations will be given at Week 12
* Nivolumab administered by intravenous (IV) infusion over 30 minutes every 2 weeks.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Dana Farber Cancer InstituteBoston, MA
Loading ...
Who Is Running the Clinical Trial?
Dana-Farber Cancer InstituteLead Sponsor
United States Department of DefenseCollaborator